(3S)-3-(3-bromo-5-chloro-2-hydroxyphenyl)-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (3S)-3-(3-bromo-5-chloro-2-hydroxyphenyl)-3-[[2-[[5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]pyridine-3-carbonyl]amino]acetyl]amino]propanoic acid
• 化学式: C₂₁H₂₂BrClN₆O₆
• 分子量: 569.8
• InChiKey: IJCLIKANGQOCLK-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  185
• 氢给体数：
  7
• 氢受体数：
  8

文献信息

• METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES
  申请人：Reiser Jochen

  公开号：US20100297139A1

  公开（公告）日：2010-11-25

  The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.
• Methods and Compositions for the Treatment of Proteinuric Diseases
  申请人：The General Hospital Corporation

  公开号：US20160296592A1

  公开（公告）日：2016-10-13

  The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.
• US9345739B2
  申请人：——

  公开号：US9345739B2

  公开（公告）日：2016-05-24
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES PROTÉINURIQUES
  申请人：GEN HOSPITAL CORP

  公开号：WO2009061448A2

  公开（公告）日：2009-05-14

  The present invention is directed to methods of treating proteinuric diseases by the administration of avß3 integrin inhibitors.
• [EN] INTEGRIN RECEPTOR ALPHA V BETA 3 AND ITS LIGAND INVOLVED IN CHRONIC ITCH<br/>[FR] RÉCEPTEUR INTÉGRINE ALPHA V BÊTA 3 ET SON LIGAND IMPLIQUÉ DANS LES DÉMANGEAISONS CHRONIQUES
  申请人：UNIV NORTH CAROLINA STATE

  公开号：WO2021055713A1

  公开（公告）日：2021-03-25

  Methods of treating pruritis (e.g., associated with atopic dermatitis or psoriasis) are described. The methods can involve administering to a subject in need of treatment an antagonist of integrin ανβ3. The antagonist can block periostin-integrin signalling. The antagonist can be, for example, an antibody, a peptide having a RGD or SVD sequence, a peptidomimetic, an amine salt, a phosphoric acid salt, or a small molecule.